arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RIGEL PHARMACEUTICALS INC

RIGL
$48.10 ▼ -0.72 (-1.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

RIGEL PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $891.8M
Dividend Yield
Revenue Growth -22.6%
Op. Margin 30.0%
ROIC 4.1%
FCF / Share $1.65
Trailing P/E 51.7x
Price / Book 2.1x
FCF Yield 3.4%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$78.70M
↓ -22.6%
Net Income Profit after all expenses
$8.65M
↓ -85.5%
Operating Margin Operating profit as % of sales
30.0%
↑ +48.2% 95th
FCF / Share Free cash flow per share
$1.65
↑ +1017.1%
Long-Term Debt Long-term obligations
$45.00M
↓ -14.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
92
Returns
99
Financial Health
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters